YOLFTbeta
Tscan Therapeutics Inc

Tscan Therapeutics Inc

TCRX · NASDAQ · Healthcare / Biotechnology

0.1606USD-0.01 (-4.40%)

Price History

Full chart

Market Stats

Previous Close0.168
Open0.174
Day Range0.1603 – 0.1749
52-Week Range0.29 – 2.57
Volume227.68K
Market Cap22.22M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.90
Dividend Yield0.00%
Beta1.07
50-Day Avg0.6463
200-Day Avg0.9543

About

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Gavin MacBeath Ph.D.
  • Employees138
  • Headquarters830 Winter Street, Waltham, MA, United States, 02451, USA
  • Websitehttps://www.tscan.com

Leadership

  • Dr. Gavin MacBeath Ph.D.CEO, Principal Financial Officer, Principal Accounting Officer & Director · b. 1970
  • Dr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory Board
  • Dr. Zoran Zdraveski J.D., Ph.D.Chief Legal & Strategy Officer and Company Secretary · b. 1970
  • Ms. Ann HargravesChief Human Resources Officer
  • Dr. Shrikanta Chattopadhyay M.D.Senior VP & Head of Translational Medicine
  • Mr. Jim MurrayChief Development Operations Officer
  • Mr. Cagan Gurer Ph.D.Senior Vice President of Discovery

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue01.08M10.14M13.54M21.05M2.82M10.32M
Growth (%)--+834.65%+33.47%+55.52%-86.62%+266.65%
Cost of Revenue9.44M20.58M3.33M5.14M88.15M4.11M2.87M
Gross Profit-9.44M-19.49M10.14M13.54M21.05M2.82M7.46M
Gross Margin--1796.50%100.00%100.00%100.00%100.00%72.24%
Operating Expense4.77M6.74M58.78M80.17M114.51M137.64M143.27M
Operating Income-14.21M-26.23M-48.64M-66.64M-93.46M-134.82M-135.81M
Operating Margin--2417.79%-479.65%-492.32%-444.00%-4787.68%-1315.38%
EBITDA-13.69M-25.00M-45.30M-59.91M-80.10M-119.74M-124.13M
EBITDA Margin--2304.42%-446.67%-442.62%-380.53%-4252.06%-1202.24%
Net Income-13.66M-26.13M-48.63M-66.22M-89.22M-127.50M-129.77M
Net Income Margin--2408.02%-479.49%-489.26%-423.86%-4527.66%-1256.81%
R&D9.44M20.58M44.95M59.82M88.15M107.35M114.15M
R&D as % of Total Revenue-1896.50%443.29%441.96%418.80%3812.14%1105.57%
Interest Expense0016.00K1.18M3.76M3.65M2.77M
Interest Expense % of Total Revenue-0.00%0.16%8.69%17.86%129.72%26.82%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets49.38M49.74M188.11M199.09M272.15M371.12M228.79M
Total Liabilities6.84M92.20M27.33M99.66M121.28M130.15M105.67M
Total Equity42.54M-42.46M160.78M99.43M150.87M240.97M123.12M
Cash41.76M34.79M161.41M120.03M133.36M178.69M152.41M
Total Debt4.89M7.43M6.04M85.98M92.43M97.38M94.14M
Net Debt-36.88M-27.36M-155.36M-34.04M-40.93M-81.31M-58.27M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.52M-3.02M-48.68M-66.50M-61.36M-110.82M-135.32M
Investing Cash Flow-1.25M-4.24M-9.94M-4.22M-60.76M-52.61M109.37M
Financing Cash Flow34.81M288.00K189.67M29.36M135.44M208.76M-336.00K
Capital Expenditure1.25M4.24M9.94M4.22M3.15M3.83M4.41M
Free Cash Flow-13.77M-7.26M-58.62M-70.73M-64.50M-114.65M-139.73M
Dividends Paid-----00
FCF to OCF109.96%240.19%120.42%106.35%105.13%103.45%103.26%
Dividend Paid to FCF-----0.00%0.00%

Earnings

Report DateApr 30, 2021Aug 19, 2021Nov 10, 2021Mar 9, 2022May 9, 2022Aug 10, 2022Nov 9, 2022Mar 8, 2023May 10, 2023Aug 10, 2023Nov 9, 2023Mar 6, 2024May 13, 2024Aug 12, 2024Nov 12, 2024Mar 5, 2025May 6, 2025Aug 12, 2025Nov 12, 2025Mar 11, 2026May 6, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate-6.40-4.09-0.48-0.73-0.62-0.72-0.71-0.70-0.75-0.78-0.44-0.29-0.24-0.28-0.29-0.29-0.28-0.32-0.33-0.27-0.16-0.29-0.26
EPS Actual-1.11-7.69-0.80-0.38-0.67-0.63-0.67-0.78-0.93-0.51-0.24-0.21-0.32-0.28-0.25-0.30-0.26-0.28-0.28-0.18-0.22-0.23-
Surprise82.66%-88.02%-66.67%47.95%-8.06%12.50%5.63%-11.43%-24.00%34.62%45.45%27.59%-33.33%0.00%13.79%-3.45%7.14%12.50%15.15%32.61%-37.50%20.69%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap22.22M
Enterprise Value15.42M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.12
Price / Book0.36
EPS-0.90
Book Value1.02
Revenue (TTM)7.11M
Gross Profit (TTM)-88.32M
EBITDA-115.66M
Profit Margin0.00%
Operating Margin-2901.33%
Return on Equity-95.81%
Return on Assets-31.53%
Shares Outstanding61.07M
Shares Float57.82M
Beta1.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 2.67
  • Strong Buy
    4
  • Buy
    4

Ownership Breakdown

Institutions
62.44%
Insiders
0.19%
Retail / Other
37.37%

Top Institutional Holders

  • Lynx1 Capital Management, LP
    8.02M11.83%
  • Bvf Inc
    5.56M8.21%
  • Baker Bros Advisors LP
    2.78M4.11%
  • Vanguard Capital Management, LLC
    2.15M3.18%
  • Two Sigma Investments LLC
    1.95M2.88%
  • BlackRock Inc
    1.84M2.72%
  • Renaissance Technologies Corp
    1.36M2.01%
  • Deer Management Co. LLC
    1.25M1.84%
  • Millennium Management LLC
    1.16M1.72%
  • Citadel Advisors Llc
    1.01M1.49%
  • Jacobs Levy Equity Management, Inc.
    808.36K1.19%
  • DC Funds, LP
    630.00K0.93%
  • Geode Capital Management, LLC
    616.95K0.91%
  • D. E. Shaw & Co LP
    548.40K0.81%
  • GSA Capital Partners LLP
    548.09K0.81%
  • Vanguard Fiduciary Trust Co
    305.77K0.45%
  • Marshall Wace Asset Management Ltd
    237.35K0.35%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.84M2.72%
  • Fidelity Extended Market Index
    299.65K0.44%
  • BlackRock Health Sciences Term Trust
    265.57K0.39%